The cachexia score (CASCO): a new tool for staging cachectic cancer patients

Area of Science:

• Oncology
• Metabolic Syndromes
• Geriatrics

Background:

• Cachexia is a complex metabolic syndrome characterized by muscle loss, often with fat mass loss, associated with underlying illness.
• Key features include weight loss, anorexia, inflammation, insulin resistance, and increased muscle protein breakdown.
• Current definitions lack staging criteria, hindering effective therapeutic strategies, especially for pre-cachexia.

Purpose of the Study:

• To develop and validate a comprehensive scoring system for staging cachexia in cancer patients.
• To address the need for patient stratification to guide therapeutic interventions.
• To include the pre-cachexia stage in the assessment.

Main Methods:

• Development of a scoring scale ranging from 0 to 100.
• Inclusion of five key factors: body weight/lean body mass loss, anorexia, inflammatory/immunological/metabolic disturbances, physical performance, and quality of life.
• Categorization of cachexia into mild, moderate, severe, and terminal phases, including pre-cachexia.

Main Results:

• The proposed score effectively stratifies patients across different stages of cachexia.
• It incorporates multiple dimensions of the cachectic syndrome, from physiological to quality of life aspects.
• The scoring system accounts for the pre-cachexia state, a critical early phase.

Conclusions:

• The developed score facilitates accurate cachexia staging in cancer patients.
• Improved staging allows for more precise and adequate therapeutic planning.
• This tool is expected to enhance clinical management of cachexia.